<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Diabetes Mellitus - Summary</title>
<style>
  body { font-family: Arial, sans-serif; line-height: 1.6; background-color: #f9f9f9; color: #333; padding: 20px; }
  h1 { color: #0066cc; }
  details { margin-bottom: 1em; background: #fff; padding: 10px; border-radius: 5px; box-shadow: 0 0 5px rgba(0,0,0,0.1); }
  summary { font-weight: bold; cursor: pointer; }
</style>
</head>
<body>

<h1>📋 Diabetes Mellitus</h1>
<p><b>Definition:</b> Group of metabolic diseases characterized by chronic hyperglycemia due to insulin deficiency and/or resistance.</p>
<p><b>Main types:</b> Type 1 (autoimmune, absolute insulin deficiency) & Type 2 (insulin resistance + relative insulin deficiency).</p>
<p><b>Goal of management:</b> Achieve glycemic targets, prevent complications, improve quality of life.</p>

<details>
<summary>🔍 Epidemiology & Risk Factors</summary>
<ul>
  <li>Type 1: ~5-10%, onset usually <20 years, HLA-DR3/4 associated.</li>
  <li>Type 2: ~90-95%, onset usually >40 years, associated with obesity, sedentary lifestyle, family history.</li>
</ul>
</details>

<details>
<summary>🔍 Pathophysiology</summary>
<ul>
  <li>Type 1: Autoimmune β-cell destruction → absolute insulin deficiency.</li>
  <li>Type 2: Insulin resistance + progressive β-cell dysfunction → relative insulin deficiency.</li>
</ul>
</details>

<details>
<summary>🔍 Clinical Features</summary>
<ul>
  <li>Classic: Polyuria, polydipsia, polyphagia, weight loss.</li>
  <li>Type 2 often asymptomatic or diagnosed on screening.</li>
  <li>Acute presentations: DKA (T1DM), HHS (T2DM).</li>
</ul>
</details>

<details>
<summary>🔍 Diagnosis</summary>
<ul>
  <li>Fasting glucose ≥126 mg/dL, or random ≥200 mg/dL with symptoms.</li>
  <li>HbA1c ≥6.5% or 2-hour OGTT ≥200 mg/dL.</li>
</ul>
</details>

<details>
<summary>🔍 Management</summary>
<ul>
  <li>Lifestyle: Diet, exercise, weight loss, smoking cessation.</li>
  <li>Pharmacologic: Metformin first-line (T2DM), insulin required (T1DM).</li>
  <li>Additional: GLP-1 RAs, SGLT2i, DPP-4 inhibitors, sulfonylureas.</li>
  <li>Monitor for complications: retinal, renal, neuropathic, cardiovascular.</li>
</ul>
</details>

<details>
<summary>🔍 Complications</summary>
<ul>
  <li>Acute: DKA, HHS, hypoglycemia.</li>
  <li>Chronic: Microvascular (retinopathy, nephropathy, neuropathy) & macrovascular (CAD, stroke, PAD).</li>
</ul>
</details>

<p style="font-size:0.9em; color:#666;">Source: Latest ADA & ISPAD guidelines.</p>

</body>
</html>
